Prostate-Specific Membrane Antigen Targeted Polymersomes for Delivering Mocetinostat and Docetaxel to Prostate Cancer Cell Spheroids

Prostate-Specific Membrane Antigen Targeted Polymersomes for Delivering Mocetinostat and Docetaxel to Prostate Cancer Cell Spheroids

Bibliographic Details
Main Authors:	Fataneh Karandish, Manas K. Haldar, Seungyong You, Amanda E. Brooks, Benjamin D. Brooks, Bin Guo, Yongki Choi, Sanku Mallik
Format:	Article
Language:	English
Published:	American Chemical Society 2016-11-01
Series:	ACS Omega
Online Access:	http://dx.doi.org/10.1021/acsomega.6b00126

Similar Items

Overexpression of claspin promotes docetaxel resistance and is associated with prostate‐specific antigen recurrence in prostate cancer
by: Takashi Babasaki, et al.
Published: (2021-08-01)

Prostate-specific antigen testing in men with metastatic castration-resistant prostate cancer treated with docetaxel chemotherapy
by: Yuh-Shyan Tsai, et al.
Published: (2015-12-01)

Undifferentiated prostate cancer treated with docetaxel
by: Masaki Kobayashi, et al.
Published: (2020-07-01)

Mocetinostat combined with gemcitabine for the treatment of leiomyosarcoma: Preclinical correlates.
by: Gonzalo Lopez, et al.
Published: (2017-01-01)

Docetaxel in the treatment of hormone-resistant prostate cancer
by: B. V. Bukharkin, et al.
Published: (2020-02-01)

Prostate-Specific antigen: An overview and its current status in the diagnosis of prostate cancer
by: Siddalingeshwar Neeli, et al.
Published: (2021-01-01)

Prostate-specific antigen and free prostate-specific antigen/prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer
by: Amal A. Hussein, et al.
Published: (2020-12-01)

NEW TRENDS IN THE USE OF TAXOTERE (DOCETAXEL) IN PROSTATE CANCER
by: O. B. Karyakin, et al.
Published: (2014-08-01)

Docetaxel (Tautax) in the treatment of hormone-refractory prostate cancer
by: I. G. Rusakov, et al.
Published: (2020-02-01)

Epithelial-Mesenchymal Transition in Docetaxel-Resistant Prostate Cancer
by: Camila Libardi do Amaral
Published: (2017-06-01)

NEW TRENDS IN THE USE OF TAXOTERE (DOCETAXEL) IN PROSTATE CANCER
by: O. B. Karyakin, et al.
Published: (2014-08-01)

Characterisation and manipulation of docetaxel resistant prostate cancer cell lines
by: Rani Sweta, et al.
Published: (2011-10-01)

Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel
by: Filippo Francini, et al.
Published: (2011-01-01)

Overcoming docetaxel resistance in prostate cancer: a perspective review
by: Clara Hwang MD
Published: (2012-11-01)

Hemorrhagic Cystitis in a Patient Receiving Docetaxel for Prostate Cancer
by: A.I. Ntekim, et al.
Published: (2010-01-01)

Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer
by: Prestwich Robin, et al.
Published: (2011-06-01)

Docetaxel and Doxorubicin Codelivery by Nanocarriers for Synergistic Treatment of Prostate Cancer
by: Ke Li, et al.
Published: (2019-12-01)

TUBB3 Reverses Resistance to Docetaxel and Cabazitaxel in Prostate Cancer
by: Yohei Sekino, et al.
Published: (2019-08-01)

Docetaxel treatment in the elderly patient with hormone refractory prostate cancer
by: Victoria J Sinibaldi
Published: (2008-01-01)

Effects of bisphosphonates alone and in combination with docetaxel : Studies in Prostate Cancer
by: Coxon, Jonathan Philip
Published: (2007)

The chemomodulatory effects of glufosfamide on docetaxel cytotoxicity in prostate cancer cells
by: Reem T. Attia, et al.
Published: (2016-06-01)

Molecular mechanisms of human Docetaxel-resistant prostate cancer cells
by: Shu-Ju Chung, et al.
Published: (2009)

Co-expression and impact of prostate specific membrane antigen and prostate specific antigen in prostatic pathologies
by: Nouira Yassin, et al.
Published: (2010-12-01)

Prostatic specific antigen for prostate cancer detection
by: Lucas Nogueira, et al.
Published: (2009-10-01)

Benign prostatic hyperplasia and prostate-specific antigen
by: Pejčić Tomislav, et al.
Published: (2015-01-01)

Prostate specific antigen negative prostate cancer
by: Birtle, A. J.
Published: (2005)

The Prostate Cancer Cells Resistant to Docetaxel as in vitro Model for Discovering MicroRNAs Predictive of the Onset of Docetaxel Resistance
by: Lorenzo Bascetta, et al.
Published: (2017-07-01)

Effectiveness of Docetaxel for Metastatic Hormone-sensitive Prostate Cancer in Clinical Practice
by: Maria Elisabeth Lendorf, et al.
Published: (2021-02-01)

Docetaxel in very elderly men with metastatic castration-resistant prostate cancer
by: Hui-Li Wong, et al.
Published: (2015-06-01)

Monotherapy with docetaxel in treatment of hormone resistant cancer of the prostate - our results
by: N K Mohanty, et al.
Published: (2003-01-01)

Clinical outcomes in castration resistant prostate cancer patients treated with docetaxel
by: Shian-Shiang Wang, et al.
Published: (2016-06-01)

Pharmacogenomic Biomarkers in Docetaxel Treatment of Prostate Cancer: From Discovery to Implementation
by: Reka Varnai, et al.
Published: (2019-08-01)

Fenofibrate Augments the Sensitivity of Drug-Resistant Prostate Cancer Cells to Docetaxel
by: Marcin Luty, et al.
Published: (2019-01-01)

Combination Effects of Docetaxel and Doxorubicin in Hormone-Refractory Prostate Cancer Cells
by: Eleftheria Tsakalozou, et al.
Published: (2012-01-01)

Impact of comorbidity on the outcome in men with advanced prostate cancer treated with docetaxel
by: Zist Andrej, et al.
Published: (2015-12-01)

Chemoresistant Role of Acetyl-tubulin in Docetaxel-Resistant Prostate Cancer Cells
by: Hong-Lin Wu, et al.
Published: (2011)

Chemoresistant Mechanism of Interleukin-8 in Docetaxel-Resistant Prostate Cancer Cells
by: Chih-Kang Liao, et al.
Published: (2013)

Docetaxel Treatment for Metastatic Hormone-sensitive Prostate Cancer in Daily Practice
by: Ietsen de Groot, et al.
Published: (2021-11-01)

Molecular mechanisms of AMPK mediated docetaxel-resistance in human prostate cancer
by: Pei-Shen Hou, et al.
Published: (2017)

Free prostate-specific antigen outperforms total prostate-specific antigen as a predictor of prostate volume in patients without prostate cancer
by: Sinan Avci, et al.
Published: (2020-04-01)